Gamelin Erick has filed 13 insider transactions across 1 company since November 2023.
Most recent transaction: a grant/award of 94946 shares of Acrivon Therapeutics, Inc. ($ACRV) on March 01, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | A | Stock Option (Right to Buy) | 94946 | $0.00 | 94,946.0000 | 38,560,464 | 9999.99% | 0.25% |
| Feb. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 471 | $1.63 | 14,812.0000 | 38,560,464 | 3.08% | 0.00% |
| Nov. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 403 | $2.24 | 15,283.0000 | 38,560,464 | 2.57% | 0.00% |
| Aug. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 403 | $1.39 | 15,686.0000 | 33,791,817 | 2.50% | 0.00% |
| May 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 403 | $1.14 | 16,089.0000 | 33,791,817 | 2.44% | 0.00% |
| March 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | A | Stock Option (Right to Buy) | 78078 | $0.00 | 78,078.0000 | 33,791,817 | 9999.99% | 0.23% |
| Feb. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 469 | $5.42 | 16,492.0000 | 33,791,817 | 2.77% | 0.00% |
| March 1, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | A | Stock Option (Right to Buy) | 45045 | $0.00 | 45,045.0000 | 22,078,190 | 9999.99% | 0.20% |
| Nov. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 402 | $7.92 | 16,961.0000 | 38,105,131 | 2.32% | 0.00% |
| Aug. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 402 | $7.02 | 17,363.0000 | 22,078,190 | 2.26% | 0.00% |
| May 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 402 | $8.36 | 17,765.0000 | 22,078,190 | 2.21% | 0.00% |
| Feb. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Development Officer | F | Common Stock | 468 | $3.40 | 18,167.0000 | 22,078,190 | 2.51% | 0.00% |
| Nov. 14, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Gamelin Erick | Chief Medical Officer | F | Common Stock | 1395 | $5.08 | 18,635.0000 | 0 | 6.96% | 0.00% |